SAN DIEGO--(BUSINESS WIRE)--GTx, Inc. (NASDAQ: GTXI) announced that results of the Phase III ADT clinical trial evaluating toremifene citrate 80 mg for the treatment of multiple side effects of androgen deprivation therapy (ADT) in men who have advanced prostate cancer were presented today during a late breaking oral session at the 2008 Annual Meeting of the American Association for Cancer Research (AACR) in San Diego. Results of the Phase III ADT clinical trial demonstrate that toremifene citrate 80 mg compared to placebo built bone and prevented fractures, reduced hot flashes, and treated other estrogen related side effects of ADT.
